One Platform. Multiple Molecules. Multiple Markets.
The Biphasic Drug Delivery Platform was designed to support differentiated pharmaceutical products across some of the largest and fastest-growing therapeutic markets in healthcare.
Compete through innovation — not commodity pricing.
Generic exclusivity expires. Differentiated formulations don't. The platform may allow partners to escape the commodity cycle and rebuild premium economics around established molecules.
This platform operates within some of the largest pharmaceutical markets in the world.
Growth trajectories through 2030 and beyond — diabetes, obesity, GLP-1, SGLT2 and value-added generics.
Why pharmaceutical companies license delivery technologies.
Patient Convenience
Simplified regimens that may support persistence and adherence.
Potential Once-Daily Dosing
Dual-peak exposure from a single oral administration.
Product Differentiation
Distinct clinical and commercial positioning vs. base generics.
New Patent Opportunities
Formulation-level IP protection layered over established molecules.
Lifecycle Management
Renewed product strategy around mature, well-characterized APIs.
Premium Commercial Positioning
Differentiated formulations command improved economics.
Transforming existing molecules into differentiated products.
Many pharmaceutical companies have shifted toward differentiated formulations and value-added generics as a strategy for escaping commodity generic pricing pressure.
The Biphasic Drug Delivery Platform aligns directly with this industry trend — adding novel delivery science on top of established, well-characterized active ingredients.
How a single platform could create a differentiated combination product.
How partners capture value through licensing, exclusivity, and commercialization support.
The platform is structured to deliver strategic value to pharmaceutical partners at every stage — from technology access through commercial launch.
Platform Licensing Access
Partners gain rights to a proven drug delivery technology applicable across multiple molecules and therapeutic areas — without starting from zero on formulation science.
- Immediate access to biphasic delivery IP
- Applicable to multiple existing APIs
- Reduced early-stage R&D risk
Exclusivity & Market Protection
Differentiated formulations open new patent estates and regulatory exclusivity pathways that standard generics cannot replicate.
- Potential new formulation patents
- 505(b)(2) data exclusivity opportunities
- Barriers to direct generic substitution
Commercialization Support
The platform is designed to accelerate partner programs through formulation optimization, regulatory strategy alignment, and capital-efficient development.
- Engineered IR + DR release profiles
- Regulatory pathway guidance
- Reduced clinical development burden
Portfolio & Franchise Expansion
A single platform license can support multiple product programs, lifecycle extensions, and entry into adjacent therapeutic markets.
- Multiple products from one platform
- New indication opportunities
- Global market applicability
Every element of the partner relationship is designed to support product differentiation, market exclusivity, and long-term franchise value — not one-time transactions.
From patent platform to long-term revenue.
Most patents protect one product. This protects a platform.
Single-product economics
Platform value creation
A central technology connecting many therapeutic opportunities.
A technology designed for repeated value creation.
The Biphasic Drug Delivery Platform represents more than a single pharmaceutical opportunity. It is a broadly applicable formulation technology designed to support differentiated products, strategic partnerships, and multiple pathways to value creation across large global healthcare markets.